Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Medistim Earnings Release 2016

Feb 17, 2017

3662_rns_2017-02-17_8d7ab47c-b567-4427-960c-5343df61977a.html

Earnings Release

Open in viewer

Opens in your device viewer

Results for fourth quarter and preliminary results for 2016 for Medistim

Results for fourth quarter and preliminary results for 2016 for Medistim

Sales for the quarter ended at MNOK 67.4 (MNOK 74.6). Sales

for 2016 ended at MNOK 268.1 (MNOK 251.4), a growth of 6.6 %.

For the year 20 MNOK of sales is lost related to the

Medtronic products. Currency neutral sales of own products

decreased with 3 MNOK or 5.7 % and was influenced by a back

order situation for the flow probes. For the year currency

neutral sales of own products increased with 9.5 %.

Operating profit (EBIT) for the quarter ended at MNOK 9.7

(MNOK 16.0). Operating profit for 2016 ended at MNOK 56.4

(MNOK 50.3). The Board suggests a dividend of NOK 1.75 per

share (NOK 1.65).

Continued strong development in the US where currency

neutral growth in sales was 13.4 %. For 2016 currency

neutral growth was 14.2 % .

Medistim launch of the New SonoQ product in India in the

fourth quarter.